TRDA PE Ratio & Valuation, Is TRDA Overvalued
This article analyzes the valuation of Entrada Therapeutics Inc (TRDA), concluding that the stock is currently undervalued. Based on a forward P/S ratio of 16.07 compared to its five-year average of 158.93, the fair price is estimated to be between $22.95 and $31.22, making it undervalued by 42.69% from its current price of $13.15. The article also details other valuation metrics like P/B ratio, FCF yield, and comparisons to competitor averages.
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of TRDA common stock for $32,375 on April 1, 2026. This sale, conducted under a Rule 10b5-1 trading plan, leaves Wentworth with 119,010 shares. The transaction occurred while TRDA stock was near its 52-week high, and InvestingPro analysis suggests the stock is overvalued despite analysts' price targets of $19-21.
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of common stock at $12.95 per share through an open-market transaction. This sale was conducted under a pre-scheduled Rule 10b5-1 trading plan adopted on March 6, 2025. After the transaction, Wentworth directly holds 119,010 shares of the company.
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth sold 2,500 shares of company stock for $32,375.00 on April 1st, reducing his position by 2.06%. This sale followed additional insider selling in March totaling approximately $312,000. Despite recent insider sales and a negative P/E ratio, analysts maintain a "Moderate Buy" rating with an average price target of $18.50 for TRDA.
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock
Wentworth Kory James, CFO of Entrada Therapeutics (NASDAQ:TRDA), sold 2,500 shares of the company's common stock for $32,375 on April 1, 2026. This transaction occurred near the stock's 52-week high, with shares having risen 53% over the past year. Following the sale, Wentworth directly owns 119,010 shares, and the sale was executed under a Rule 10b5-1 trading plan.
(TRDA) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA), indicating positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It outlines distinct trading strategies including position, momentum breakout, and risk hedging, accompanied by multi-timeframe signal analysis and specific entry/exit points with risk-reward ratios.
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA)
Cantor Fitzgerald initiated coverage on Entrada Therapeutics (NASDAQ:TRDA) with an "overweight" rating, contributing to a consensus "Moderate Buy" rating and a target price of $18.50. Despite beating EPS estimates, the company's revenue significantly missed expectations, and it remains unprofitable, trading around $12.62 with a market cap of $483 million. Recent insider selling by the CFO and COO, totaling over $508K in shares, accounted for a substantial portion of insider transactions, with institutional investors holding the majority of the stock.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Entrada Therapeutics (NASDAQ:TRDA) has received a "Moderate Buy" consensus recommendation from five brokerages, with an average 12-month target price of $18.50. Despite some insider selling from the COO and CFO in March, the company's insiders still own 7.59% of the stock. Entrada Therapeutics recently beat EPS estimates but missed revenue expectations in its latest quarterly report.
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Entrada Therapeutics (NASDAQ:TRDA) from "hold" to "sell." Despite mixed analyst ratings and the company beating EPS expectations, it missed revenue targets, remains unprofitable, and recently saw insider share sales. The consensus rating for TRDA is still a "Moderate Buy" with an average price target of $18.50.
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)
Analysts are showing bullish sentiment towards two healthcare stocks: Entrada Therapeutics Inc (TRDA) and CG Oncology, Inc. (CGON). Joseph Thome from TD Cowen maintained a Buy rating on Entrada Therapeutics with a price target of $20.00, while Sam Slutsky from LifeSci Capital reiterated a Buy rating on CG Oncology with a price target of $108.00. Both companies have an analyst consensus of Strong Buy, indicating significant upside potential from current levels.
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)
This article highlights two healthcare stocks, Entrada Therapeutics Inc (TRDA) and CG Oncology, Inc. (CGON), that analysts are optimistic about. Entrada Therapeutics received a Buy rating from TD Cowen with a $20.00 price target, representing a 67.4% upside. CG Oncology also received a Buy rating from LifeSci Capital, with a $108.00 price target, and maintains a Strong Buy consensus rating from analysts.
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA)
This article analyzes the historical performance of investing $1,000 in Entrada Therapeutics, Inc. (TRDA) over various periods, showing its returns compared to the S&P 500. It also provides a detailed overview of Entrada Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for neuromuscular, ocular, and metabolic diseases using its proprietary Endosomal Escape Vehicle (EEV™) technology. The company's pipeline includes multiple programs for Duchenne muscular dystrophy and inherited retinal diseases, highlighting its strategic partnerships and community engagement.
Responsive Playbooks and the TRDA Inflection
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA), highlighting a weak near-term sentiment that could shift to stronger mid and long-term outlooks. It presents three AI-generated trading strategies with an exceptional 86.0:1 risk-reward setup targeting a 24.9% gain, and emphasizes multi-timeframe signal analysis for various holding periods.
Insider Sell Alert: Nathan Dowden Sells Shares of Entrada Therap
Nathan Dowden, President & COO of Entrada Therapeutics Inc (TRDA), sold 15,010 shares of the company on March 10, 2026. This transaction is part of a trend showing more insider sells than buys for TRDA over the past year. The stock is considered significantly overvalued based on its GF Value, trading at $13.04 with a GF Value of $2.14.
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock
Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden sold 3,116 shares of company stock for $40,570.32 on March 9, reducing his ownership by 1.46%. While Entrada Therapeutics recently reported better-than-expected EPS, revenue missed estimates. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $18.50.
Entrada Therapeutics (NASDAQ:TRDA) COO Sells $155,216.70 in Stock
Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden sold 11,894 shares of company stock for a total of $155,216.70. This transaction reduced his total holdings by 5.65% to 198,588 shares. The company's stock is trading at $13.50, and analysts have a consensus "Moderate Buy" rating with an $18.50 price target.
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares
Kory James Wentworth, CFO of Entrada Therapeutics (NASDAQ:TRDA), sold a total of 24,465 shares in early March across three transactions for approximately $312,000, now owning 132,898 shares valued at $1.73 million. Despite beating EPS estimates last quarter, the company missed revenue targets and reported significant negative margins. The stock trades near its 52-week high, with substantial institutional ownership and a "Moderate Buy" consensus rating from analysts, who set an average target price of $18.50.
Understanding the Setup: (TRDA) and Scalable Risk
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA), indicating strong sentiment across all horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near, mid, and long-term horizons. The analysis highlights elevated downside risk due to the lack of additional long-term support signals.
Kory Wentworth sells TRDA shares via 10b5-1 plan (TRDA) reported to SEC
Kory Wentworth reported planned sales of Entrada Therapeutics (TRDA) common stock through a 10b5-1 plan across three days in early March 2026, totaling sales of 16,639 shares for a combined proceeds of $199,307.27. The transactions, handled by Morgan Stanley Smith Barney LLC, were detailed in an SEC Form 144 filing and involved shares derived from previously exercised stock options and restricted stock units. The article emphasizes that these sales are part of a scheduled plan rather than discretionary, with the filing providing transparency on the insider's transactions.
Entrada Therapeutics (TRDA) CFO sells 16,477 shares under 10b5-1 plan
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold a total of 16,477 shares of company common stock in open-market transactions on March 9 and March 10, 2026. These sales, valued at approximately $214,379, were executed under a pre-established Rule 10b5-1 trading plan adopted in March 2025. Following these transactions, Wentworth directly holds 121,510 shares of Entrada common stock.
Entrada Therapeutics (TRDA) CFO executes planned stock sale
Entrada Therapeutics CFO Kory James Wentworth sold 7,988 shares of common stock on March 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in March 2025. The shares were sold at a weighted average price of $12.2549, with individual prices ranging from $11.80 to $12.57. Following this transaction, Wentworth directly holds 137,987 shares in Entrada Therapeutics.
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales
Entrada Therapeutics' CFO, Kory James Wentworth, received new equity compensation grants including 66,600 stock options and 44,600 restricted stock units (RSUs) on March 1, 2026, which will vest through March 1, 2030. The filing also detailed mandatory sell-to-cover transactions for tax withholding, where the company automatically sold a total of 8,651 shares on March 2 and 3, 2026. These sales were not discretionary trades but were executed to cover statutory tax obligations, leaving Wentworth with 145,975 common shares and 66,600 options after these transactions.
[144] Entrada Therapeutics, Inc. SEC Filing
This article details an SEC Form 144 filing by Entrada Therapeutics, Inc. (TRDA), indicating proposed sales of securities by Nathan Dowden. The filing outlines two prior sales of common stock in early March 2026 and mentions Restricted Stock Units. The overall filing impact and sentiment are noted as neutral.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts
Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received a consensus "Moderate Buy" rating from analysts, with an average one-year target price of $18.50. The company reported quarterly EPS of ($0.94), beating estimates, but missed on revenue. Insider selling by the CFO was noted, while institutional investors hold a significant stake in the company.
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics CFO Kory James Wentworth sold 7,988 shares of the company's stock on March 4th for a total of $97,853, reducing his stake by 5.47%. Despite reporting better-than-expected EPS for the last quarter, the company generated low revenue and sustained significant negative margins. Analysts have a "Moderate Buy" rating with an average price target of $18.50, and institutional investors hold approximately 86% of the stock.
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA
Royce & Associates LP increased its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 54.8% in Q3, now owning 345,507 shares valued at $2,004,000. Other institutional investors have also adjusted their holdings, with institutional ownership now at 86.39%. Despite some negative sentiment regarding earnings forecasts, analysts have a "Moderate Buy" rating for Entrada Therapeutics with a consensus target price of $18.50.
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA)
A Form 144 filing reported that Morgan Stanley Smith Barney LLC Executive Financial Services submitted a notice for 7,988 restricted stock units of TRDA to be sold. Additionally, the filing detailed recent dispositions by Kory Wentworth, who sold 5,712 common shares on March 3, 2026, and 2,939 common shares on March 2, 2026, with reported proceeds of $67,152.56 and $34,262.57, respectively. The filing is categorized as neutral in impact and sentiment, indicating routine compliance reporting.
TRDA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Entrada Therapeutics, Inc. (TRDA), including its income statement, balance sheet, and cash flow statement for fiscal year 2025 and previous years. It highlights key financial metrics such as declining revenue, negative operating and net margins, and a low Piotroski F-Score indicating weak financial health, despite strong liquidity and low debt. The company's cash runway is estimated at approximately 8 months due to significant operating cash burn.
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales
Entrada Therapeutics CEO Dipal Doshi was granted new equity awards, including 139,400 restricted stock units and options for 208,000 shares, both at $0.00 strike price, vesting over several years. Following these awards, a total of 29,050 shares were automatically sold by the company to cover Doshi's tax withholding obligations at weighted average prices of $11.6579 and $11.7564 per share. After these transactions, Doshi directly owns 526,014 shares of Entrada Therapeutics common stock.
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals
Entrada Therapeutics' President & COO, Nathan J. Dowden, reported receiving 55,800 restricted stock units (RSUs) and an option for 83,200 shares on March 1, 2026. These equity compensation grants have vesting schedules extending through March 2030. To cover statutory tax withholding obligations, 21,261 shares were automatically disposed of on March 2 and 3, 2026, at weighted average prices around $11.66-$11.76, explicitly noted as non-discretionary trades.
Entrada Therapeutics Announces Inducement Grants
Entrada Therapeutics, a clinical-stage biopharmaceutical company, has granted 12,990 restricted stock units (RSUs) to two new non-executive employees under its 2025 Inducement Equity Plan. These grants, approved by the Compensation Committee, serve as a material inducement for their employment, adhering to Nasdaq Listing Rule 5635(c)(4). This move highlights the company's growth and strategy to attract and retain talent in the biotech industry.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced inducement grants of 12,990 restricted stock units (RSUs) to two new non-executive employees under its 2025 Inducement Equity Plan. These grants, effective March 1, 2026, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, subject to continuous employment, to attract and retain talent.
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entrada Therapeutics (NASDAQ: ENTX) with a $20.00 price target, citing the company's progress with its exon-skipping DMD candidates in Phase 1/2 studies and the undervalued DM1 collaboration program. Selvaraju believes the company's current enterprise value does not fully reflect its extensive DMD franchise or the potential of the partnered DM1 asset. This sentiment is echoed by Oppenheimer, which also reiterated a Buy rating with a $21.00 price target.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. announced incentive grants of 12,990 restricted stock units (RSUs) to two newly-hired non-executive employees under its 2025 Inducement Equity Plan. These grants, effective March 1, 2026, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, with one-fourth vesting on the one-year anniversary and subsequent quarterly vesting, subject to continuous employment.
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Entrada Therapeutics (NASDAQ:TRDA) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with an average target price of $18.50. Despite beating EPS expectations last quarter, the company significantly missed revenue targets and displays deeply negative net margins. Institutional ownership remains high at 86.39%, with several major hedge funds increasing or initiating positions.
The Technical Signals Behind (TRDA) That Institutions Follow
This article analyzes the technical signals for Entrada Therapeutics Inc. (NASDAQ: TRDA) based on AI models, identifying strong near and mid-term sentiment. It outlines three institutional trading strategies tailored to different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis also provides multi-timeframe signal strength, support, and resistance levels for TRDA.
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside
Entrada Therapeutics (TRDA) is a clinical-stage biopharmaceutical company with innovative drug delivery technology and a focus on RNA and protein-based treatments. Analysts are optimistic about TRDA, with an average target price suggesting a 54% upside, despite current financial challenges typical of early-stage biotech firms. The company's EEV™ technology aims to revolutionize treatments for neuromuscular and ocular diseases, positioning it as a compelling, albeit risky, investment opportunity.
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline
Entrada Therapeutics, a clinical-stage biopharmaceutical company, is advancing its pipeline of intracellular genetic medicines, primarily focusing on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and ocular diseases. The company expects significant data readouts in 2026 from its DMD programs (ENTR‑601‑44 and ENTR‑601‑45) and regulatory progress for ENTR‑601‑50 and ENTR‑601‑51. Additionally, its partnered DM1 program (VX‑670) with Vertex is anticipated to complete enrollment and dosing in mid-2026, while a new ocular candidate (ENTR-801) for Usher syndrome type 2A is also moving forward.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Entrada Therapeutics announced its financial results for Q4 and full year 2025, alongside significant progress in its clinical development pipeline. The company reported a cash runway into Q3 2027 with $295.7 million in cash, cash equivalents and marketable securities as of December 31, 2025. Key clinical milestones include positive data monitoring committee recommendations for its Duchenne muscular dystrophy programs and advancing new candidates for Usher syndrome type 2A and other inherited retinal diseases.
Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives
Entrada Therapeutics (TRDA) reported a significant quarterly revenue slump in Q4 2025, with revenue falling to US$1.3 million and a basic EPS loss of US$0.94. Despite analysts forecasting 38.7% annual revenue growth over the next three years, earnings are expected to continue declining, leaving the company unprofitable. The company's high P/S ratio of 18x, compared to peers, indicates that investors are banking heavily on future growth while current performance shows substantial losses, highlighting considerable execution risk.
DMD trials advance as Entrada extends cash runway to Q3 2027
Entrada Therapeutics reported its Q4 and full-year 2025 financial results, including a net loss of $143.8 million. Despite the loss, an independent Data Monitoring Committee recommended initiating Cohort 2 of the ELEVATE-44-201 study at an increased dose for Duchenne muscular dystrophy (DMD) treatment, and the company nominated ENTR-801 for Usher syndrome type 2A. Entrada also confirmed a cash runway extending into Q3 2027 with $295.7 million in cash, cash equivalents, and marketable securities.
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS
Entrada Therapeutics (NASDAQ:TRDA) reported earnings per share of ($0.94), beating analyst estimates by $0.38, though revenue of $1.3 million fell short of the $7.41 million forecast. Despite remaining unprofitable with negative return on equity and net margin, the company's shares rose 6.8% to $12.79. Institutional ownership stands at 86.4%, and analysts have a "Moderate Buy" consensus rating with an average price target of $18.50.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Entrada Therapeutics has announced its financial results for Q4 and full year 2025, alongside significant advancements in its clinical development pipeline. The company is on track to report key clinical data for its Duchenne muscular dystrophy (DMD) programs (ELEVATE-44-201 and ELEVATE-45-201) in 2026, and an Independent Data Monitoring Committee has recommended escalating the dose for a cohort in the ELEVATE-44-201 study. With a cash position of $295.7 million by December 31, 2025, Entrada projects its cash runway to extend into the third quarter of 2027, supporting further expansion of its therapeutic pipeline.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Entrada Therapeutics announced its financial results for Q4 and full-year 2025, along with significant progress in its clinical-stage pipeline. The company reported a cash runway extending into Q3 2027 and provided updates on its Duchenne muscular dystrophy (DMD) programs and preclinical pipeline for inherited retinal diseases. A positive independent Data Monitoring Committee recommendation for initiating Cohort 2 of the ELEVATE-44-201 study at an increased dose was also highlighted.
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline
Entrada Therapeutics reported a significant financial shift in 2025, moving from a net income of $65.6 million in 2024 to a net loss of $143.8 million. This change was primarily due to a sharp decline in collaboration revenue, from $210.8 million to $25.4 million, after the substantial completion of the VX-670 research plan, coupled with increased research and development spending on its genetic medicines pipeline, particularly for Duchenne muscular dystrophy (DMD) programs. Despite the losses, the company ended 2025 with $295.7 million in cash, providing a runway into Q3 2027 to continue advancing its clinical programs and pursue multiple expected data readouts in 2026 for its DMD pipeline.
Entrada Therapeutics, Inc. SEC 10-K Report
Entrada Therapeutics, Inc. has released its annual 10-K report detailing its financial performance, business operations, and strategic initiatives. The company reported a significant net loss of $(143.8) million in 2025, primarily due to decreased collaboration revenue and increased R&D expenses, compared to a net income of $65.6 million in 2024. Despite financial challenges, Entrada is advancing multiple clinical programs for Duchenne muscular dystrophy, Usher syndrome 2A, and myotonic dystrophy type 1, leveraging its EEV platform and strategic partnerships, while anticipating funding into Q3 2027.
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX)
This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR), and Argenx Se (ARGX). Oppenheimer analysts Kostas Biliouris and Jeff Jones reiterated Buy ratings for Entrada Therapeutics and Kymera Therapeutics, respectively, with specific price targets. Morgan Stanley's Sean Laaman also maintained a Buy rating for Argenx Se, indicating a strong positive outlook across the sector.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Entrada Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant advancements in its clinical development pipeline for Duchenne muscular dystrophy (DMD) and other genetic medicines. The company maintains a strong cash position, with a runway expected into Q3 2027, backed by $295.7 million in cash, cash equivalents, and marketable securities. Key upcoming milestones include multiple clinical data readouts for its DMD programs throughout 2026 and the expansion of its preclinical pipeline into inherited retinal diseases.
Earnings Summary: Entrada Therapeutics Q4
Entrada Therapeutics (NASDAQ: TRDA) released its Q4 earnings on February 26, 2026, reporting an EPS of $-0.94, which beat the estimated $-1.22 by 22.95%. Despite beating EPS estimates, revenue for the quarter was down $36.10 million compared to the same period last year. The company's stock price dropped by 0.58% the day after last quarter's earnings announcement, where it missed EPS estimates.
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
This article discusses Entrada Therapeutics (TRDA) stock, which recently increased by 5.6%. It poses the question of whether there is further upside potential for the stock, implying an analysis of its recent performance and future prospects.
